Abstract
Epidemiological surveillance typically relies on reported incidence of cases or hospitalizations, which can suffer significant reporting lags, biases and under-ascertainment. Here, we evaluated the potential of viral loads measured by RT-qPCR cycle threshold (Ct) values to track epidemic trends. We used SARS-CoV-2 RT-qPCR results from hospital testing in Massachusetts, USA, municipal testing in California, USA, and simulations to identify predictive models and covariates that maximize short-term epidemic trend prediction accuracy. We found SARS-CoV-2 Ct value distributions correlated with epidemic growth rates under real-world conditions. We fitted generalized additive models to predict log growth rate or direction of reported SARS-CoV-2 case incidence using features of the time-varying population Ct distribution and assessed the models’ ability to track epidemic dynamics in rolling two-week windows. Observed Ct value distributions accurately predicted epidemic growth rates (growth rate RMSE ∼ 0.039-0.052) and direction (AUC ∼ 0.72-0.78). Performance degraded during periods of rapidly changing growth rate. Predictive models were robust to testing regimes and sample sizes; accounting for population immunity or symptom status yielded no substantial improvement. Trimming Ct value outliers improved performance. These results indicate that analysis of Ct values from routine PCR tests can help monitor epidemic trends, complementing traditional incidence metrics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JAH is supported by a Wellcome Trust Early Career Award (grant 225001/Z/22/Z). This work was supported in part by the Francis P. Tally, MD, Fellowship in the Division of Geographic Medicine and Infectious Disease (JAP). This project has been funded in part by contract 200-2016-91779 with the Centers for Disease Control and Prevention (CDC). Disclaimer: The findings, conclusions, and views expressed are those of the authors and do not necessarily represent the official position of the CDC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Harvard T.H. Chan School of Public Health waived ethical approval for this work. IRB of Brigham & Women's Hospital waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† These authors jointly supervised the work.
Data & code availability
Data and analysis code are available online at https://github.com/gradlab/ct-nowcasting [NOTE: we will update this to a Zenodo DOI before publication].
